The present invention relates to a fat reducing agent for reducing the amount of accumulated fat in hepatocytes, comprising fibroblast growth factor 9 as an active ingredient, and the treatment of fatty liver disease, particularly NAFLD, comprising the fat reducing agent as an active ingredient. And / or pharmaceuticals for prevention. ADVANTAGE OF THE INVENTION According to this invention, it becomes possible to improve the fatty liver in fatty liver disease, especially NASH / NAFLD, and / or reduce the accumulation of fat in the liver, and in addition to exercise therapy or in addition to exercise therapy, It becomes possible to provide a direct therapeutic means and / or preventive means for congenital liver disease. The present invention also relates to reducing blood cholesterol and / or suppressing an increase in blood cholesterol in a subject suffering from or possibly suffering from fatty liver disease, particularly NAFLD, containing FGF9 or a functional equivalent thereof as an active ingredient. It relates to the medicine.本発明は、線維芽細胞増殖因子９を有効成分として含む、肝細胞における脂肪蓄積量を低減させるための脂肪低減剤、並びに当該脂肪低減剤を有効成分として含む、脂肪性肝疾患特にＮＡＦＬＤの治療及び／又は予防のための医薬に関する。本発明によれば、脂肪性肝疾患特にＮＡＳＨ／ＮＡＦＬＤにおける脂肪肝の改善及び／又は肝臓への脂肪の蓄積を低減させることが可能となり、運動療法とは別の又は運動療法に加えて、脂肪性肝疾患に対して直接的な治療手段及び／又は予防手段を提供することが可能となる。また本発明は、ＦＧＦ９又はその機能的等価物を有効成分として含む、脂肪性肝疾患特にＮＡＦＬＤに罹患した又は罹患するおそれのある対象の血中コレステロールを低減させる及び／又はその増加を抑制するための医薬に関する。
